Narjust Florez
MD
Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Jul 30, 2024
Episode
230
Soundcloud
Share
In this episode of Lung Cancer Considered, host Dr. Narjust Florez and two esteemed oncology colleagues discuss an evolving hot topic: the use of immune checkpoint inhibitors in the treatment of patients with molecular-driven non-small cell lung cancer.
Guest
Biagio Ricciuti
MD
Thoracic Medical Oncologist and Data Scientist
Dana-Farber Cancer Institute
Harvard Medical School
Erin Schenk
MD
Assistant Professor of Medicine in the section of Medical Oncology
University of Colorado
Director of the Schenk Laboratory
